CNS Fast-tracked by FDA for Treatment of Recurrent Glioblastoma Multiforme

 FDA Fast Track Designation for Berubicin highlights the serious unmet medical need for new treatments for glioblastoma multiforme (GBM)

- Company recently commenced enrollment in potentially pivotal study evaluating Berubicin in the treatment of adult recurrent glioblastoma multiforme

https://finance.yahoo.com/news/fda-grants-fast-track-designation-123500841.html